WO2009013724A2 - Trimetal-arene clusters with anticancer activity - Google Patents
Trimetal-arene clusters with anticancer activity Download PDFInfo
- Publication number
- WO2009013724A2 WO2009013724A2 PCT/IB2008/052998 IB2008052998W WO2009013724A2 WO 2009013724 A2 WO2009013724 A2 WO 2009013724A2 IB 2008052998 W IB2008052998 W IB 2008052998W WO 2009013724 A2 WO2009013724 A2 WO 2009013724A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- independently
- alkyl
- formula
- clusters
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 59
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 28
- 201000011510 cancer Diseases 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 206010027476 Metastases Diseases 0.000 claims abstract description 10
- 230000009401 metastasis Effects 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 229910052707 ruthenium Inorganic materials 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229910052703 rhodium Inorganic materials 0.000 claims description 7
- 229910052762 osmium Inorganic materials 0.000 claims description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 125000000129 anionic group Chemical group 0.000 claims description 5
- 229910052741 iridium Inorganic materials 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 229910052711 selenium Inorganic materials 0.000 claims description 4
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 150000002739 metals Chemical class 0.000 claims description 3
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 2
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 7
- 239000010948 rhodium Substances 0.000 description 7
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 6
- 229960004316 cisplatin Drugs 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 5
- 229940125890 compound Ia Drugs 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 4
- -1 for example Inorganic materials 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 150000002902 organometallic compounds Chemical class 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 150000003303 ruthenium Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 241001120493 Arene Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229940125661 RAPTA-C Drugs 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001449 anionic compounds Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- SQNZJJAZBFDUTD-UHFFFAOYSA-N durene Chemical compound CC1=CC(C)=C(C)C=C1C SQNZJJAZBFDUTD-UHFFFAOYSA-N 0.000 description 2
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229910001412 inorganic anion Inorganic materials 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000002097 pentamethylcyclopentadienyl group Chemical group 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- PQNPKQVPJAHPSB-UHFFFAOYSA-N 1,4,7-trithionane Chemical compound C1CSCCSCCS1 PQNPKQVPJAHPSB-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229930007927 cymene Natural products 0.000 description 1
- YBPJNJSKPUAMKZ-UHFFFAOYSA-N decane Chemical compound CCCCCCCCC[CH2-] YBPJNJSKPUAMKZ-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- YUWFEBAXEOLKSG-UHFFFAOYSA-N hexamethylbenzene Chemical compound CC1=C(C)C(C)=C(C)C(C)=C1C YUWFEBAXEOLKSG-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 150000002907 osmium Chemical class 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- BPEVHDGLPIIAGH-UHFFFAOYSA-N ruthenium(3+) Chemical class [Ru+3] BPEVHDGLPIIAGH-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910006400 μ-Cl Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F17/00—Metallocenes
- C07F17/02—Metallocenes of metals of Groups 8, 9 or 10 of the Periodic Table
Definitions
- the present invention relates to new medicaments, pharmaceutical compositions and methods of treatment of cancer on the basis of triruthenium clusters disclosed herein.
- organometallic compounds specifically on ruthenium(II)-arene compounds which show excellent antiproliferative properties both in vitro and in vivo. It has been found that a structurally diverse range of compounds all exhibit interesting properties. For example, a wide range of arenes can be tolerated and the arene can even be replaced by cyclopentadienyl, pentamethylcyclopentadienyl or the sulphur macrocycle 1,4,7-trithiacyclononane without affecting the in vitro activity significantly.
- the present inventors have found unusually high cytotoxic activity of compounds of formula (I) against cancer cells.
- the present invention provides, in a first aspect, compounds of formula (I) for use as a medicament,
- M 1 , M 2 and M 3 are metals selected independently from each other from Ru, Os, Ir, Rh, Co and Fe;
- X is selected from O, N, P, S, Se, or Te;
- Y 1 , Y 2 , Y3 are independently of each other selected from H, OH, SRi, and PRiR 2 , wherein R 1 , R 2 are, independently of each other, selected from aryl and alkyl, said alkyl or aryl optionally being substituted and optionally comprising one or more heteroatoms;
- a 1 , A 2 and A 3 are independently of each other selected from ⁇ 6 -arenes, ⁇ 5 -cyclopentadienyls, or derivatives of these; and,
- Z is a pharmaceutically acceptable anionic species.
- the present invention further provides compounds of formula (I) for the treatment of cancer including both primary tumours, but also the treatment of metastasis.
- the present invention also provides a pharmaceutical composition comprising the compound according to formula (I).
- the present invention provides a method for the treatment of cancer, the method comprising the step of administering to an individual in need thereof a pharmaceutically effective amount of the compound according to formula (I).
- Figure 1 shows trinuclear (Ia, Ib) and tetranuclear (2a-2c) ruthenium-arene clusters evaluated for anticancer activity.
- Figures 2a and 2b show dose-response curves of exposure of compounds Ia ( Figure 2a) and 2b ( Figure 2b) to A2780 and 2780cis ovarian carcinoma cell lines, determined using the MTT assay.
- the present invention relates to trinuclear metal clusters of formula (II) below and their use as medicaments, in particular in the treatment and/or prophylaxis of cancer, including metastasis.
- M 1 , M 2 and M 3 are metals selected independently from each other from Ru, Os, Ir, Rh, Co and Fe;
- X is selected from O, N, P, S, Se, or Te;
- Y 1 , Y 2 , Y3 are independently of each other selected from H, OH, SRi, and PRiR 2 , wherein R 1 , R 2 are, independently of each other, selected from aryl and alkyl, said alkyl or aryl optionally being substituted and optionally comprising one or more heteroatoms; A 1 , A 2 and A3 are independently of each other selected from ⁇ 6 -arenes, ⁇ 5 -cyclopentadienyls, ⁇ 3 -l,4,7-trithiacyclononane, ⁇ 3 -l,4,7-triazacyclononane or derivatives of these.
- the clusters of formula (II) may be charged or neutral. Preferably, they are positively charged and provided in the form of a pharmaceutically acceptable salt. Preferably, the compounds carry the charge +1.
- the clusters of formula (II) are positively charged, they are provided together with a pharmaceutically acceptable anion.
- the anion is [Z], preferably [Z] " , where [Z] stands for any organic or pharmaceutically acceptable inorganic anion.
- [Z] " can be selected from Cl “ , Br “ , I “ , BF 4 “ , PF 6 “ , BPh 4 “ , CF 3 SO 3 “ , NO 3 " , SbF 6 " , amongst a vast number of known pharmaceutically acceptable inorganic anions.
- citrate, succinate, ascorbate and tartrate are mentioned here as suitable organic anions.
- pharmaceutically acceptable refers to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of a subject (e.g. human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- Mi, M 2 and M 3 may be the same or different.
- they are independently selected from Ru (ruthenium), Rh (rhodium) and Os (osmium), Ir (iridium), Co (cobalt) and Fe (iron).
- Ru ruthenium
- Rh rhodium
- Os osmium
- Ir iridium
- Co cobalt
- Fe iron
- Ru ruthenium
- Rh rhodium
- Ir iridium
- Co cobalt
- Fe iron
- Ru ruthenium
- Rh Rhodium
- Ir iridium
- Co cobalt
- Fe iron
- Ru, Rh, Os and Ir more preferably from Ru, Rh, and Os.
- Ru for example Ru(II).
- Mi, M 2 and M 3 are all the same metal.
- X is selected from O, N, P, S, Se, or Te. Preferably it is O.
- Yi, Y 2 , Y 3 are independently of each other selected from H, OH, SRi, and PRiR 2 , wherein Ri, R 2 are, independently of each other, selected from aryl and alkyl, said alkyl or aryl optionally being substituted and optionally comprising one or more heteroatoms.
- R 1 , R 2 may be linear, branched and/or cyclic alkyls. Preferably, they include from 1 to 30 carbons, more preferably 1 to 20, 1 to 10, and most preferably 2 to 6 carbon atoms.
- the alkyls may be substituted.
- hydrogen atoms may be replaced by halogens, for example, F, Cl, and/or Br.
- Ri and/or R 2 may comprise one or more heteroatoms, for example O, S, N, P, or halogens.
- Ri and R 2 may be linked with each other so as to provide, together with the P, a cyclic system, which may include one or more rings.
- R 1 , R 2 may be aryls, which may be substituted, for example by linear, branched and/or cyclic alkyls optionally comprising heteroatoms as defined above.
- the aryl may comprise one or more heteroatoms, too, in particular O and/or N. Hydrogen atoms may be partly or totally replaced by halogens and/or other substituents.
- the aryl is preferably C5-C30, more preferably C6-C20, most preferably C6-C10.
- Y 1 , Y 2 , Y3 represent hydrogen atoms.
- a 1 , A 2 and/or A 3 may all be the same, all different, or two of Ai -A 3 may be the same and one different.
- a 1 , A 2 and/or A 3 are selected from compounds of formula (III) or (IV):
- any one of R10-R15, or, if A 1 , A 2 and/or A 3 is (are) (IV), respectively, any one of R10-R14 are independently selected from H, C1-C20 alkyl, C2- 20 alkenyl, C2-C20 alkynyl, C6-C22 aryl, said alkyl, alkenyl, alkynyl being linear, branched or cyclic, and said alkyl, alkenyl, alkynyl and aryls being optionally substituted and optionally comprising one or more heteroatoms, wherein any of the residues R10-R15 or R10-R14, respectively may be covalently connected with one or more other residues of R10-R15 or R10-R14, respectively, to form one or several rings fused to the ring of formula (III) or (IV), respectively.
- a 1 , A 2 and/or A 3 are benzene, methylbenzene, hexamethylbenzene, cymene, for example o-, m- or /?-cymene, durene, cyclopentadienyl and pentamethylcyclopentadienyl.
- R10-R15 or R10-R14, in the compounds of formula (III) or (IV), respectively are selected independently from each other from H and Cl-ClO, more preferably C1-C5 alkyls.
- any one of R10-R15 or R10-R14, in the compounds of formula (III) or (IV), respectively, is selected independently from the other from H, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, isobutyl, 1-ethyl-propyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, for example.
- halogens in particular F, Cl, and Br, Cl -C 15, preferably Cl-ClO, more preferably C1-C5 alkyls, alkenyls, alkynyls and aryls (which may or may not comprise heteroatoms, in particular N, O, P, S),
- one two or all three of Ai, A 2 and/or A 3 are covalently connected to each other, for example by alkylene or other linking groups.
- the compound according to the present invention is selected from [( ⁇ 6 -C 6 H 6 )( ⁇ 6 -C 6 Me 6 ) 2 Ru 3 ( ⁇ -H) 3 ( ⁇ 3 -O)][Z] and [( ⁇ 6 -C 6 H 6 )( ⁇ 6 -l, 4- 1 PrC 6 H 4 Me) ( ⁇ 6 -CeMe 6 )Ru 3 ( ⁇ -H) 3 ( ⁇ 3 -O)][Z] wherein Z is a pharmaceutically acceptable anionic species.
- Mi-M 3 ; Ai - A 3 ; Yi - Y 3 ; and X are as defined above; and wherein, the compound of formula (V) is positively charged and provided together with an anionic species so that the provided compound is a salt.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising the compound according to formula (I) and/or (II). While it is possible for the active compound to be administered alone, it is preferably to present it as a pharmaceutical composition (e.g. formulation) comprising at least one active compound, as defined above, together with one or more pharmaceutically acceptable carriers, adjuvants, excipients, diluents, fillers, buffers, stabilisers, preservatives, lubricants, or other materials well known to those skilled in the art and optionally other therapeutic or prophylactic agents. Suitable carriers, excipients, etc. can be found in standard pharmaceutical texts, for example, Remington's Pharmaceutical Sciences, 18 th edition, Mack Publishing Company, Easton, Pa., 1990.
- the compounds disclosed herein are useful in the treatment and prophylaxis of cancer, in particular also against secondary cancers (metastasis).
- cancers which may be treated by the active compounds include, but are not limited to, a carcinoma, for example a carcinoma of the bladder, breast, colon (e.g. colorectal carcinomas such as colon adenocarcinoma and colon adenoma), kidney, epidermal, liver, lung, for example adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas, oesophagus, gall bladder, ovary, pancreas e.g.
- a carcinoma for example a carcinoma of the bladder, breast, colon (e.g. colorectal carcinomas such as colon adenocarcinoma and colon adenoma), kidney, epidermal, liver, lung, for example adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas, oesophagus, gall bladder, ovary, pancreas e.g.
- exocrine pancreatic carcinoma, stomach, cervix, thyroid, prostate, or skin for example squamous cell cercinoma
- a hematopoietic tumour of lymphoid lineage for example leukaemia, acute lymphocytic leukaemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non- Hodgkin's lymphoma, hairy cell lymphoma , or Burkett's lymphoma
- a hematopoietic tumour of myeloid lineage for example acute or chronic myelogenous leukemias, myelodysplastic syndrome, or promyelocytic leukaemia
- thyroid follicular cancer a tumour of mesenchymal origin, for example fibrosarcoma or habdomyosarcoma
- a tumour of the central or peripheral nervous system for example astrocytoma, neuroblastoma, glioma or schannom
- the compounds of the present invention may be used as pharmaceutically active principles, for example in a pharmaceutical composition. For example, they are useful as medicaments.
- the compounds of the present invention are preferably used as medicaments against cancer. Accordingly, the present invention relates to the use of the organometallic compounds comprising a structure of formulae (I), (II) and (V) in therapeutic cancer treatment.
- the invention provides compounds comprising a structure of formulae (I), (II) and (V), or prodrugs or solvates thereof ("active compounds”), for use in a method of treatment of the human or animal body.
- a method of treatment may comprise administering to such an individual a therapeutically-effective amount of the compound of the present invention, preferably in the form of a pharmaceutical composition.
- treatment as used herein in the context of treating a condition pertains generally to treatment and therapy, whether of a human or animal (e.g. in veterinary applications), in which some therapeutic effect is achieved, for example, the inhibition of the progress of the condition, and includes a reduction in the rate of the progress, a halt in the rate of the progress, amelioration of the condition, and cure of the condition.
- the condition usually is associated with suffering, from psychological and/or physical pain, with the individual being in need of a treatment.
- Treatment as a prophylactic measure i.e. prophylaxis
- prophylaxis is also included.
- the compound of the invention or pharmaceutical composition comprising the active compound may be administered to an individual by any convenient route of administration, whether systemically /peripherically or at the site of desired action, including but not limited to, oral (e.g. by ingestion), topical (including e.g. transdermal, intranasal, ocular, buccal and sublingual), pulmonary (e.g. by inhalation or insufflation therapy using an aerosol, e.g.
- oral e.g. by ingestion
- topical including e.g. transdermal, intranasal, ocular, buccal and sublingual
- pulmonary e.g. by inhalation or insufflation therapy using an aerosol, e.g.
- vaginal for example by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, subcuticula, subcapsular, intraorbital, intraperitoneal, intratracheal, subarachnoid, and intrasternal, by implant of a depot (e.g. subcutaneously or intramuscularly).
- a depot e.g. subcutaneously or intramuscularly.
- FIG. 1 This figure also shows compounds with nuclearity of 4, in particular [( ⁇ 6 -C 6 H 6 ) 4 Ru 4 ( ⁇ -H) 4 ] [BF 4 J 2 2a, 2b and [( ⁇ 6 - C6H 6 ) 4 Ru4( ⁇ -H)3( ⁇ -OH)][Cl]2 2c.
- the ability of the compounds to inhibit cancer cell viability was performed against two different ovarian cancer cell lines, A2780 and its cisplatin-resistant strain A2780cisR, which exhibit a 6-fold increase in cisplatin resistance.
- the effects of the clusters on the cancer cell growth were evaluated after an exposure period of 72 hours using the MTT [3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay which measures mitochondrial dehydrogenase activity as an indication of cell viability.
- the IC50 values for the inhibition of cell viability of the complexes are listed in Table 1.
- the dose-response curves for Ia and Ib against the two cell lines are illustrated in Figures 2a and 2b.
- RAPTA-C 100 > 100
- the triruthenium clusters are highly cytotoxic in comparison to the tetraruthenium clusters, since the two classes of clusters exhibit one major difference with respect to their chemical reactivity.
- the triruthenium clusters present a hydrophobic pocket and a ⁇ 3-oxo ligand, which could form supramolecular interactions with arenes and other functions. Indeed, the hydrophobic pocket spanned by the three arene ligands can accommodate arene moieties, while the ⁇ 3-oxo ligand interacts strongly with hydroxyl groups.
- the tetraruthenium clusters do not contain a hydrophobic pocket or a ⁇ 3 -oxo ligand, and, without wishing to be bound by theory, it is therefore plausible to attribute the cytotoxic activity of Ia and Ib to a supramolecular recognition process within the cancer cell. Since hydrophobic arene units and hydroxyl groups are usually buried inside proteins, it is possible that a highly selective process is in operation. Clearly, further experiments are required to prove such a hypothesis, but nevertheless, the excellent activity of Ia and Ib in the ovarian cell lines is striking.
- Example 3 Effect of compound Ia on lung metastasis in vivo
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to new medicaments, pharmaceutical compositions and methods of treatment of cancer. Disclosed are trimetallic clusters for use as a medicament, in particular in the treatment of cancer including metastasis. Preferably, the compounds are provided in the form of pharmaceutically acceptable salts. Preferred compound include trinuclear ruthenium- arene clusters as exemplified by the compounds 1a and 1b shown in Figure 1.
Description
TRIMETAL-ARENE CLUSTERS WITH ANTICANCER ACTIVITY
Field of the Invention
The present invention relates to new medicaments, pharmaceutical compositions and methods of treatment of cancer on the basis of triruthenium clusters disclosed herein.
Background and Problems to be Solved
Recent years have witnessed a tremendous increase in research into anticancer compounds based on ruthenium with two ruthenium coordination compounds that have a different spectrum of activity to platinum drugs currently undergoing clinical evaluation. Notably, the differing activity is assigned to a different mode of action guided by the high affinity of ruthenium(III) compounds toward proteins.
More recently, interest has focused on organometallic compounds, specifically on ruthenium(II)-arene compounds which show excellent antiproliferative properties both in vitro and in vivo. It has been found that a structurally diverse range of compounds all exhibit interesting properties. For example, a wide range of arenes can be tolerated and the arene can even be replaced by cyclopentadienyl, pentamethylcyclopentadienyl or the sulphur macrocycle 1,4,7-trithiacyclononane without affecting the in vitro activity significantly. It has even been found that some rhodium and osmium analogues, evaluated in HT29 colon carcinoma, A549 lung carcinoma and T47D breast carcinoma cell lines in vitro, display activities that are comparable to the related ruthenium(II)-arene complexes. A feature of many of these compounds, notably those with the l,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane (pta) ligand, is that although the activity is lower than that of cisplatin and related Pt(II) compounds in vitro, the activity against metastatic (secondary) tumours evaluated in vivo is high.
C. S. Allardyce, P. J. Dyson (2002), Journal of Cluster Science, 12, 563, disclose metal clusters and their potential application in cancer therapy.
C. S. Allardyce, P. J. Dyson, D. J. Ellis, P. A. Salter, R. Scopelliti (2003), Journal of Organometallic Chemistry 668, 35, disclose ruthenium(II)-arene complexes and their antibiotic and antiviral properties.
In view of the above, it is an objective to identify still further compounds useful in the treatment of cancer and in particular of metastasis.
It is an objective to provide compounds which are still more cytotoxic against cancer cells.
It is a particular objective to provide further ruthenium-based organometallic compounds that are at least as effective as or even more effective than the organometallic compounds known so far.
Summary of the Invention
Remarkably, the present inventors have found unusually high cytotoxic activity of compounds of formula (I) against cancer cells.
Accordingly, the present invention provides, in a first aspect, compounds of formula (I) for use as a medicament,
(i) wherein,
M1, M2 and M3 are metals selected independently from each other from Ru, Os, Ir, Rh, Co and Fe; X is selected from O, N, P, S, Se, or Te;
Y1, Y2, Y3 are independently of each other selected from H, OH, SRi, and PRiR2, wherein R1, R2 are, independently of each other, selected from aryl and alkyl, said alkyl or aryl optionally being substituted and optionally comprising one or more heteroatoms;
A1, A2 and A3 are independently of each other selected from η6-arenes, η5-cyclopentadienyls, or derivatives of these; and,
Z is a pharmaceutically acceptable anionic species.
The present invention further provides compounds of formula (I) for the treatment of cancer including both primary tumours, but also the treatment of metastasis.
The present invention also provides a pharmaceutical composition comprising the compound according to formula (I).
In a further aspect, the present invention provides a method for the treatment of cancer, the method comprising the step of administering to an individual in need thereof a pharmaceutically effective amount of the compound according to formula (I).
Brief Description of the Drawings
In the figures,
Figure 1 shows trinuclear (Ia, Ib) and tetranuclear (2a-2c) ruthenium-arene clusters evaluated for anticancer activity.
Figures 2a and 2b show dose-response curves of exposure of compounds Ia (Figure 2a) and 2b (Figure 2b) to A2780 and 2780cis ovarian carcinoma cell lines, determined using the MTT assay.
Detailed Description of the Preferred Embodiments
In its general scope, the present invention relates to trinuclear metal clusters of formula (II) below and their use as medicaments, in particular in the treatment and/or prophylaxis of cancer, including metastasis.
M1, M2 and M3 are metals selected independently from each other from Ru, Os, Ir, Rh, Co and Fe;
X is selected from O, N, P, S, Se, or Te;
Y1, Y2, Y3 are independently of each other selected from H, OH, SRi, and PRiR2, wherein R1, R2 are, independently of each other, selected from aryl and alkyl, said alkyl or aryl optionally being substituted and optionally comprising one or more heteroatoms; A1, A2 and A3 are independently of each other selected from η6-arenes, η5-cyclopentadienyls, η3-l,4,7-trithiacyclononane, η3-l,4,7-triazacyclononane or derivatives of these.
The clusters of formula (II) may be charged or neutral. Preferably, they are positively charged and provided in the form of a pharmaceutically acceptable salt. Preferably, the compounds carry the charge +1.
If the clusters of formula (II) are positively charged, they are provided together with a pharmaceutically acceptable anion. Preferably, the anion is [Z], preferably [Z]", where [Z] stands for any organic or pharmaceutically acceptable inorganic anion. As mere illustrative examples [Z]" can be selected from Cl", Br", I", BF4 ", PF6 ", BPh4 ", CF3SO3 ", NO3 ", SbF6 ", amongst a vast number of known pharmaceutically acceptable inorganic anions. For purely illustrative purposes, citrate, succinate, ascorbate and tartrate, are mentioned here as suitable organic anions.
The term "pharmaceutically acceptable", as used herein pertains to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of a subject (e.g. human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
Within the context of this specification the word "comprises" is taken to mean "includes, among other things". It is not intended to be construed as "consists only of.
In the compounds of formula (I) or (II) above, Mi, M2 and M3 may be the same or different. Preferably they are independently selected from Ru (ruthenium), Rh (rhodium) and Os (osmium), Ir (iridium), Co (cobalt) and Fe (iron). Preferably they are selected from Ru, Rh, Os and Ir, more preferably from Ru, Rh, and Os. Most preferably they are Ru, for example Ru(II).
Preferably Mi, M2 and M3 are all the same metal.
In the compounds of formula (I) or (II) above, X is selected from O, N, P, S, Se, or Te. Preferably it is O.
In the compounds of formula (I) or (II) above, Yi, Y2, Y3 are independently of each other selected from H, OH, SRi, and PRiR2, wherein Ri, R2 are, independently of each other, selected from aryl and alkyl, said alkyl or aryl optionally being substituted and optionally comprising one or more heteroatoms.
R1, R2 may be linear, branched and/or cyclic alkyls. Preferably, they include from 1 to 30 carbons, more preferably 1 to 20, 1 to 10, and most preferably 2 to 6 carbon atoms. The alkyls may be substituted. For example, hydrogen atoms may be replaced by halogens, for example, F, Cl, and/or Br. Ri and/or R2 may comprise one or more heteroatoms, for example O, S, N, P, or halogens. In PRiR2, Ri and R2 may be linked with each other so as to provide, together with the P, a cyclic system, which may include one or more rings.
R1, R2 may be aryls, which may be substituted, for example by linear, branched and/or cyclic alkyls optionally comprising heteroatoms as defined above. The aryl may comprise one or more heteroatoms, too, in particular O and/or N. Hydrogen atoms may be partly or totally replaced by halogens and/or other substituents. The aryl is preferably C5-C30, more preferably C6-C20, most preferably C6-C10.
Preferably, Y1, Y2, Y3 represent hydrogen atoms.
A1, A2 and/or A3 may all be the same, all different, or two of Ai -A3 may be the same and one different. For example, According to a preferred embodiment, A1, A2 and/or A3 are selected from compounds of formula (III) or (IV):
Examples of A1, A2 and/or A3, mentioned here for the mere purpose of illustration, are benzene, methylbenzene, hexamethylbenzene, cymene, for example o-, m- or /?-cymene, durene, cyclopentadienyl and pentamethylcyclopentadienyl.
Preferably, R10-R15 or R10-R14, in the compounds of formula (III) or (IV), respectively, are selected independently from each other from H and Cl-ClO, more preferably C1-C5 alkyls.
For example, any one of R10-R15 or R10-R14, in the compounds of formula (III) or (IV), respectively, is selected independently from the other from H, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, isobutyl, 1-ethyl-propyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, for example.
Substituents of residues R10-R15 or R10-R14, may be selected from halogens, in particular F, Cl, and Br, Cl -C 15, preferably Cl-ClO, more preferably C1-C5 alkyls, alkenyls, alkynyls and aryls (which may or may not comprise heteroatoms, in particular N, O, P, S), -OH, -COOH, =0, -SH, =S, -C≡N, -NO2, -NRiR2, with Ri and R2 being, independently of each other, H or as defined above with respect to PRiR2, for example-NH2.
According to an embodiment, one two or all three of Ai, A2 and/or A3 are covalently connected to each other, for example by alkylene or other linking groups.
According to a preferred embodiment, the compound according to the present invention is selected from [(η6-C6H6)(η6-C6Me6)2Ru3(μ-H)3(μ3-O)][Z] and [(η6-C6H6)(η6-l, 4-1PrC6H4Me) (η6-CeMe6)Ru3(μ-H)3(μ3-O)][Z] wherein Z is a pharmaceutically acceptable anionic species. In these compounds, [(η6-C6H6)(η6-C6Me6)2Ru3(μ-H)3(μ3-O)] corresponds to the cationic part of compound Ia shown in Figure 1 and [(η6-C6H6)(η6-l,4-1PrC6H4Me)(η6-C6Me6)Ru3(μ- H)3(μ3-O)] corresponds to the cationic part of compound Ib shown in Figure 1.
The compounds encompassed by the present invention also concern compounds of the formula (V):
[(η-Ai)(η-A2)(η-A3)M3(μ2-Yi)(μ2-Y2)(μ2-Y3)(μ3-X)] (V) wherein, η stands at each time for either η6 or η5;
Mi-M3; Ai - A3; Yi - Y3; and X are as defined above; and wherein, the compound of formula (V) is positively charged and provided together with an anionic species so that the provided compound is a salt.
The present invention also relates to a pharmaceutical composition comprising the compound according to formula (I) and/or (II). While it is possible for the active compound to be administered alone, it is preferably to present it as a pharmaceutical composition (e.g. formulation) comprising at least one active compound, as defined above, together with one or more pharmaceutically acceptable carriers, adjuvants, excipients, diluents, fillers, buffers, stabilisers, preservatives, lubricants, or other materials well known to those skilled in the art
and optionally other therapeutic or prophylactic agents. Suitable carriers, excipients, etc. can be found in standard pharmaceutical texts, for example, Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Company, Easton, Pa., 1990.
The compounds disclosed herein are useful in the treatment and prophylaxis of cancer, in particular also against secondary cancers (metastasis).
Examples of cancers which may be treated by the active compounds include, but are not limited to, a carcinoma, for example a carcinoma of the bladder, breast, colon (e.g. colorectal carcinomas such as colon adenocarcinoma and colon adenoma), kidney, epidermal, liver, lung, for example adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas, oesophagus, gall bladder, ovary, pancreas e.g. exocrine pancreatic carcinoma, stomach, cervix, thyroid, prostate, or skin, for example squamous cell cercinoma; a hematopoietic tumour of lymphoid lineage, for example leukaemia, acute lymphocytic leukaemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non- Hodgkin's lymphoma, hairy cell lymphoma , or Burkett's lymphoma; a hematopoietic tumour of myeloid lineage, for example acute or chronic myelogenous leukemias, myelodysplastic syndrome, or promyelocytic leukaemia; thyroid follicular cancer; a tumour of mesenchymal origin, for example fibrosarcoma or habdomyosarcoma; a tumour of the central or peripheral nervous system, for example astrocytoma, neuroblastoma, glioma or schannoma; melanoma; seminoma; teratocarcinoma; osteosarcoma; xenoderoma pigmentoum; keratoctanthoma; thyroid follicular cancer; or Kaposi's sarcoma.
The compounds of the present invention may be used as pharmaceutically active principles, for example in a pharmaceutical composition. For example, they are useful as medicaments. The compounds of the present invention are preferably used as medicaments against cancer. Accordingly, the present invention relates to the use of the organometallic compounds comprising a structure of formulae (I), (II) and (V) in therapeutic cancer treatment.
The invention provides compounds comprising a structure of formulae (I), (II) and (V), or prodrugs or solvates thereof ("active compounds"), for use in a method of treatment of the human or animal body. A method of treatment may comprise administering to such an individual a therapeutically-effective amount of the compound of the present invention, preferably in the form of a pharmaceutical composition. The term treatment as used herein in the context of treating a condition, pertains generally to treatment and therapy, whether of a human or animal (e.g. in veterinary applications), in which some therapeutic effect is achieved, for example, the inhibition of the progress of the condition, and includes a reduction in the rate of the progress, a halt in the rate of the progress, amelioration of the condition, and
cure of the condition. The condition usually is associated with suffering, from psychological and/or physical pain, with the individual being in need of a treatment. Treatment as a prophylactic measure (i.e. prophylaxis) is also included.
The compound of the invention or pharmaceutical composition comprising the active compound may be administered to an individual by any convenient route of administration, whether systemically /peripherically or at the site of desired action, including but not limited to, oral (e.g. by ingestion), topical (including e.g. transdermal, intranasal, ocular, buccal and sublingual), pulmonary (e.g. by inhalation or insufflation therapy using an aerosol, e.g. through mouth or nose), rectal, vaginal, parenteral, for example by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, subcuticula, subcapsular, intraorbital, intraperitoneal, intratracheal, subarachnoid, and intrasternal, by implant of a depot (e.g. subcutaneously or intramuscularly).
The following non- limiting examples illustrate the present invention.
Examples
Example 1 : Synthesis of Compounds of the Invention
A first ruthenium cluster with a nuclearity of three, [(η6-C6H6)(η6-CeMe6)2Ru3(μ-H)3(μ3- O)][BF4] Ia, was prepared as disclosed in M. Faure, M. Jahncke, A. Neels, H. Stoeckli- Evans, G. Sϋss-Fink (1999), Polyhedron 18, 2679.
Another ruthernium cluster, [(η6-C6H6)(η6-l,4-1PrC6H4Me)(η6-C6Me6)Ru3(μ-H)3(μ3-O)] [BF4] Ib, was prepared as disclosed in L. Vieille-Petit, G. Sϋss-Fink, B. Therrien, T. R. Ward, H. Stoeckli-Evans, G. Labat, L. Karmazin-Brelot, A. Neels, T. Bϋrgi, R. G. Finke, C. M. Hagen (2005), Organometallics, 24, 6104.
The compounds are shown in Figure 1. This figure also shows compounds with nuclearity of 4, in particular [(η6-C6H6)4Ru4(μ-H)4] [BF4J2 2a,
2b and [(η6- C6H6)4Ru4(μ-H)3(μ-OH)][Cl]2 2c. Compound 2b is new, and was isolated from the reaction of [(η6-C6H5Me)Ru(μ-Cl)Cl]2 in water with molecular hydrogen (55 atm, 6O0C), which gives the tetranuclear hexahydrido cluster [(η6-C6H5Me)4Ru4(μ-H)6]2+ that further reacts slowly with oxygen to form the tetrahydrido cluster isolated as the tetrafluoroborate salt 2b.
Example 2: Effect of Compounds Ia and Ib on Cancer Cell Viability
The ability of the compounds to inhibit cancer cell viability was performed against two different ovarian cancer cell lines, A2780 and its cisplatin-resistant strain A2780cisR, which exhibit a 6-fold increase in cisplatin resistance. The effects of the clusters on the cancer cell growth were evaluated after an exposure period of 72 hours using the MTT [3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay which measures mitochondrial dehydrogenase activity as an indication of cell viability. The IC50 values for the inhibition of cell viability of the complexes are listed in Table 1. In addition, the dose-response curves for Ia and Ib against the two cell lines are illustrated in Figures 2a and 2b.
Table 1. Inhibition of cell viability (IC50) of complexes on A2780 and A2780cisR ovarian carcinoma cell lines after 72 hours of incubation, determined using MTT assay.
Cnmnniiiuls A278Ω Λ27SnrkR
Cisplatin 1.5 ±0.3 8.7 ±1.6
RAPTA-C > 100 > 100
Ia 9.8 ±0.2 14.6 ±0.7
Ib 9.1 ±0.9 28.9 ±2.8
2a > 100 > 100
2b > 100 > 100
2c > 100 > 100
From Table 1 it is clear that, while both the triruthenium clusters (Ia and Ib) are remarkably active in both cell lines, both being slightly less active in the cisplatin-resistant A2780cisR cell line, the tetraruthenium clusters (2a-2c) are not cytotoxic. Although the values are about 3-6 times higher than cisplatin, they are low in comparison to ruthenium-based complexes, typically 20-30 times lower than the class of antimetastatic ruthenium(II)-arene complexes containing the l,3,5-triaza-7-phospha-adamantane ligand (RAPTA-C). The activities are also significantly higher than organometallic ruthenium complexes containing imidazolium, dihydroxypyridyl, ferrocenyl and polyoxomolybdenum clusters screened for inhibition of cancer cell growth ability against the same cell lines under similar condition. To date, they are some of the most active ruthenium anticancer compounds reported.
Without wishing to be bound by theory, it is interesting to consider why the triruthenium clusters are highly cytotoxic in comparison to the tetraruthenium clusters, since the two
classes of clusters exhibit one major difference with respect to their chemical reactivity. The triruthenium clusters present a hydrophobic pocket and a μ3-oxo ligand, which could form supramolecular interactions with arenes and other functions. Indeed, the hydrophobic pocket spanned by the three arene ligands can accommodate arene moieties, while the μ3-oxo ligand interacts strongly with hydroxyl groups. By contrast, the tetraruthenium clusters do not contain a hydrophobic pocket or a μ3-oxo ligand, and, without wishing to be bound by theory, it is therefore tempting to attribute the cytotoxic activity of Ia and Ib to a supramolecular recognition process within the cancer cell. Since hydrophobic arene units and hydroxyl groups are usually buried inside proteins, it is possible that a highly selective process is in operation. Clearly, further experiments are required to prove such a hypothesis, but nevertheless, the excellent activity of Ia and Ib in the ovarian cell lines is striking.
Example 3: Effect of compound Ia on lung metastasis in vivo
Experiments for determining the effect of compound Ia of the invention on metastasis was conducted in vivo with the model of Lewis lung carcinoma implanted subcutaneously in the flank of B6D2F1 mice. Compound Ia of the invention was administered by intra peritoneal injection on day 8 after tumour implant. 22 days after tumour implant, lung metastasis were evaluated. Compound Ia, given at 32.5 mg/kg, reduced metastasis number and weight of metastasis, respectively, by 45.8% and 49.2%.
Claims
1. Compounds of formula (I) for use as a medicament,
(i) wherein,
M1, M2 and M3 are metals selected independently from each other from Ru, Os, Ir, Rh, Co and Fe;
X is selected from O, N, P, S, Se, or Te;
Y1, Y2, Y3 are independently of each other selected from H, OH, SRi, and PRiR2, wherein R1, R2 are, independently of each other, selected from aryl and alkyl, said alkyl or aryl optionally being substituted and optionally comprising one or more heteroatoms;
A1, A2 and A3 are independently of each other selected from η6-arenes, η5-cyclopentadienyls, or derivatives of these; and,
Z is a pharmaceutically acceptable anionic species.
2. The compounds of claim 1, wherein A1, A2 and/or A3 are selected from compounds of
3. The compounds of claim 2, wherein, if A1, A2 and/or A3, is (are) (III), any one of R10- Ri5, or, if Ai, A2 and/or A3 is (are) (IV), respectively, any one of R10-R14, is independently selected from H and a C1-C5 alkyl.
4. The compounds according to any one of the preceding claims, wherein M1, M2 and M3 are Ru.
5. The compounds according to any one of the preceding claims, wherein X is oxygen (O).
6. The compounds according to any one of the preceding claims, wherein Y1, Y2, Y3 are hydrogen (H).
7. The compounds according to any one of the preceding claims, which are selected from [(η6-C6H6)(η6-C6Me6)2Ru3(μ-H)3(μ3-O)] [Z] and
[(η6-C6H6)(η6-l,4-1PrC6H4Me)(η6-C6Me6)Ru3(μ-H)3(μ3-O)][Z] wherein Z is a pharmaceutically acceptable anionic species.
8. Compounds of any one of the preceding claims for the treatment of cancer.
9. Compounds of any one of the preceding claims for the treatment of metastasis.
10. A pharmaceutical composition comprising the compound according to formula (I) and/or according to any one of the preceding claims.
11. Method for the treatment of cancer, the method comprising the step of administering to an individual in need thereof a pharmaceutically effective amount of the compound according to formula (I) as defined in any one of Claims 1 to 10.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07113278.1 | 2007-07-26 | ||
| EP07113278A EP2019109A1 (en) | 2007-07-26 | 2007-07-26 | Trimetal-arene clusters with anticancer activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2009013724A2 true WO2009013724A2 (en) | 2009-01-29 |
| WO2009013724A3 WO2009013724A3 (en) | 2009-03-19 |
Family
ID=38724544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2008/052998 WO2009013724A2 (en) | 2007-07-26 | 2008-07-25 | Trimetal-arene clusters with anticancer activity |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP2019109A1 (en) |
| WO (1) | WO2009013724A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2409697A1 (en) | 2010-07-20 | 2012-01-25 | Université de Neuchâtel | Medicaments Based on Dinuclear Ruthenium, Osmium and Iron Complexes Comprising Triply Bridging Thiolato, Selenolato, Alkoxo and/or Amido Ligands |
| WO2012138988A2 (en) * | 2011-04-07 | 2012-10-11 | The Research Foundation Of The City University Of New York | Organometallic anti-cancer complexes |
-
2007
- 2007-07-26 EP EP07113278A patent/EP2019109A1/en not_active Withdrawn
-
2008
- 2008-07-25 WO PCT/IB2008/052998 patent/WO2009013724A2/en active Application Filing
Non-Patent Citations (2)
| Title |
|---|
| FAURE, MATTHIEU ET AL: "Cluster build-up in aqueous solution: synthesis, structure, protonation and catalytic properties of the trinuclear cation [(.eta.6-C6H6)(.eta.6- C6Me6)2Ru3(.mu.2-H)3(.mu.3-O)]+" POLYHEDRON , 18(20), 2679-2685 CODEN: PLYHDE; ISSN: 0277-5387, 1999, XP002460634 cited in the application * |
| VIEILLE-PETIT, LUDOVIC ET AL: "Synthesis and Characterization of Tetrahedral Ru3O Clusters with Intrinsic Framework Chirality: A Chiral Probe of the Intact Cluster Catalysis Concept" ORGANOMETALLICS , 24(25), 6104-6119 CODEN: ORGND7; ISSN: 0276-7333, 2005, XP002460635 cited in the application * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2409697A1 (en) | 2010-07-20 | 2012-01-25 | Université de Neuchâtel | Medicaments Based on Dinuclear Ruthenium, Osmium and Iron Complexes Comprising Triply Bridging Thiolato, Selenolato, Alkoxo and/or Amido Ligands |
| WO2012010616A1 (en) | 2010-07-20 | 2012-01-26 | Université De Neuchâtel | Medicaments based on dinuclear arene ruthenium complexes comprising bridging thiolato, selenolato or alkoxo ligands |
| WO2012138988A2 (en) * | 2011-04-07 | 2012-10-11 | The Research Foundation Of The City University Of New York | Organometallic anti-cancer complexes |
| WO2012138988A3 (en) * | 2011-04-07 | 2013-02-28 | The Research Foundation Of The City University Of New York | Organometallic anti-cancer complexes |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009013724A3 (en) | 2009-03-19 |
| EP2019109A1 (en) | 2009-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Patra et al. | The medicinal chemistry of ferrocene and its derivatives | |
| Lazarević et al. | Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives | |
| Li et al. | Half-sandwich iridium (III) and ruthenium (II) complexes containing P^ P-chelating ligands: A new class of potent anticancer agents with unusual redox features | |
| Kelland et al. | Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes | |
| Köpf-Maier et al. | Transition and main-group metal cyclopentadienyl complexes: preclinical studies on a series of antitumor agents of different structural type | |
| US8980875B2 (en) | Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof | |
| US9408853B2 (en) | Iridium/rhodium anti-cancer compounds | |
| Crespo | Cyclometallated platinum (IV) compounds as promising antitumour agents | |
| Jürgens et al. | Mechanistic insights into gold organometallic compounds and their biomedical applications | |
| Bai et al. | Advances in thiosemicarbazone metal complexes as anti-lung cancer agents | |
| Lord et al. | Organometallic iridium arene compounds: the effects of C-donor ligands on anticancer activity | |
| Auzias et al. | Arene–ruthenium complexes with ferrocene-derived ligands: Synthesis and characterization of complexes of the type [Ru (η6-arene)(NC5H4CH2NHOC-C5H4FeC5H5) Cl2] and [Ru (η6-arene)(NC3H3N (CH2) 2O2C–C5H4FeC5H5) Cl2] | |
| Kocsis et al. | Synthesis, structure and in vitro cytostatic activity of ferrocene—Cinchona hybrids | |
| WO1991011450A1 (en) | New cis-platinum complexes with chelating amines and sulphinyl carboxylates | |
| WO2009013724A2 (en) | Trimetal-arene clusters with anticancer activity | |
| ITMI940610A1 (en) | PLATINUM TRINUCLEAR CATIONIC COMPLEXES FOR ANTI-CANCER ACTIVITIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| Jaiswal et al. | Synthesis, characterizations, crystal structure and anticancer activity of Mn (II), Co (II) and Ni (II) complexes of N′-cyclohexyl-2-thiophene-carbonyl hydrazine carbothioamide | |
| Curado et al. | Heterometallic Complexes as Anticancer Agents | |
| JP2005536487A (en) | Ruthenium anticancer complex | |
| Yang et al. | Synthesis and in vitro antitumor activity of novel iridium (III) complexes with enantiopure C2-symmetrical vicinal diamine ligands | |
| Zhao et al. | Anti-tumoral titanium (IV) complexes stabilized with phenolato ligands and structure-activity relationship | |
| EP0232785B1 (en) | Hydroxylated 1,2-diaminocyclohexane platinum complexes | |
| Pradhan et al. | Quantum Chemical Investigation on Hydrolysis of Orally Active Organometallic Ruthenium (II) and Osmium (II) Anticancer Drugs and Their Interaction with Histidine | |
| US10973849B2 (en) | Rhenium complexes and methods of use for treating cancer | |
| De Pascali et al. | Synthesis, characterization and cytotoxicity of novel Pt (II) κ2O, O′-acetylacetonate complexes with nitrogen ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08789452 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2008789452 Country of ref document: EP |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08789452 Country of ref document: EP Kind code of ref document: A2 |